First US Trachea Transplant Patient Breathing Freely
So far, patient has not had any complications or signs of rejection
Miscellaneous Respiratory Disorders
Xolair Approved for Adults With Nasal Polyps
The approval was supported by data from the phase 3 POLYP 1 (N=138) and POLYP 2 (N=127) trials evaluating the efficacy and safety of Xolair in adults with nasal polyps who had an inadequate response to nasal corticosteroids.
Antifibrotic Therapy Gets Orphan Drug Status for Systemic Sclerosis
ACE-1334 is a TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands.
ATS Issues Guideline on Home Oxygen Therapy for COPD, ILD
Long-term oxygen therapy strongly recommended for adults with COPD, ILD who have severe chronic resting hypoxemia
CDC Reports Cases of Multisystem Inflammatory Syndrome in Adults
Small data set indicates that adults with current or previous SARS-CoV-2 can develop hyperinflammatory syndrome.
Benralizumab Looks Promising in Nasal Polyps Trial
The 56-week OSTRO trial evaluated the efficacy and safety of benralizumab, an interleukin-5 antagonist, in 413 adult patients with severe nasal polyposis.
Dupixent Prefilled Pen Approval Provides Additional Administration Option
The FDA has approved a prefilled pen formulation of Dupixent (dupilumab; Sanofi and Regeneron), providing another option for administering the treatment.
Brensocatib Receives Breakthrough Tx Status for Non-Cystic Fibrosis Bronchiectasis
The FDA has granted Breakthrough Therapy designation to brensocatib (INS1007; Insmed) for the treatment of adults with non-cystic fibrosis bronchiectasis for reducing exacerbations.
First Study Investigating Antibody Treatment for COVID-19 Begins
The first patients have been dosed in a phase 1 trial evaluating a potential antibody therapy designed to treat coronavirus disease 2019. These patients received treatment at major medical centers in the US, including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.
ATS Provides Interim Guidance for Management of COVID-19
Hydroxychloroquine, chloroquine suggested for hospitalized patients with COVID-19, severe pneumonia.
